[Medications for smoking cessation. New advice concerning important neuropsychiatric effects].
Sabourin
Guy
G
D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use; D001552:Benzazepines / Q000627:therapeutic use; D016642:Bupropion / Q000627:therapeutic use; D003863:Depression / Q000188:drug therapy; D006801:Humans; D018722:Nicotinic Agonists / Q000627:therapeutic use; D011810:Quinoxalines / Q000627:therapeutic use; D016540:Smoking Cessation / Q000379:methods* / Q000523:psychology*; D014481:United States; D014486:United States Food and Drug Administration; D000068580:Varenicline
D018687:Antidepressive Agents, Second-Generation; D001552:Benzazepines; D018722:Nicotinic Agonists; D011810:Quinoxalines; D016642:Bupropion; D000068580:Varenicline